Company & Industry Overviews
A Deeper Look at Atara Biotherapeutics’ ATA129, ATA520, and ATA230
In April 2017, Atara Biotherapeutics (ATRA) entered into an agreement with Merck (MRK) to evaluate ATA129 in combination with Merck’s Keytruda.
How Does Novavax Compare to Its Competitors?
Novavax posted a negative EPS (earnings per share) of -$0.39 in 2Q15, which is better than its 1Q15 EPS.